CO7091183A2 - A metabolite of iloperidone for use in the treatment of psychiatric disorders - Google Patents
A metabolite of iloperidone for use in the treatment of psychiatric disordersInfo
- Publication number
- CO7091183A2 CO7091183A2 CO14224666A CO14224666A CO7091183A2 CO 7091183 A2 CO7091183 A2 CO 7091183A2 CO 14224666 A CO14224666 A CO 14224666A CO 14224666 A CO14224666 A CO 14224666A CO 7091183 A2 CO7091183 A2 CO 7091183A2
- Authority
- CO
- Colombia
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- treatment
- sterilizer
- iloperidone
- Prior art date
Links
- 208000020016 psychiatric disease Diseases 0.000 title abstract 2
- XMXHEBAFVSFQEX-UHFFFAOYSA-N iloperidone Chemical class COC1=CC(C(C)=O)=CC=C1OCCCN1CCC(C=2C3=CC=C(F)C=C3ON=2)CC1 XMXHEBAFVSFQEX-UHFFFAOYSA-N 0.000 title 1
- 150000003839 salts Chemical class 0.000 abstract 6
- 239000003693 atypical antipsychotic agent Substances 0.000 abstract 1
- 229940127236 atypical antipsychotics Drugs 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Abstract
La presente invención se refiere un método de tratamiento de un paciente que sufre de un trastorno psiquiátrico que comprende administrar internamente al paciente una cantidad eficaz de R-P88, o una sal farmacéuticamente aceptable de la misma, o un éster de R-P88 o una sal farmacéuticamente aceptable de tal éster, una o dos veces por día, así como a una composición farmacéutica que comprende R-P88 o una sal farmacéuticamente aceptable de la misma, o un éster de R-P88 o una sal farmacéuticamente aceptable de un éster de R-P88, y un vehículo farmacéuticamente aceptable. Y al uso del R-P88 o una sal farmacéuticamente aceptable del mismo, o un éster de R-P88 o una sal farmacéuticamente aceptable de un éster de R-P88 para su uso en la fabricación de un medicamento útil para el tratamiento de un trastorno susceptible de tratamiento con un antipsicótico atípico.The present invention relates to a method of treatment of a patient suffering from a psychiatric disorder that comprises administering to the patient internally an effective amount of R-P88, or a pharmaceutically acceptable salt thereof, or a sterile of R-P88 or a pharmaceutically acceptable salt of such sterilizer, once or twice a day, as well; as to a pharmaceutical composition comprising R-P88 or a pharmaceutically acceptable salt thereof, or a R-P88 sterilizer or a pharmaceutically acceptable salt of a R-P88 sterilizer. , and a pharmaceutically acceptable vehicle. And upon use of R-P88 or a pharmaceutically acceptable salt thereof, or a R-P88 sterilizer or a pharmaceutically acceptable salt of an R-P88 sterilizer for use in manufacturing of a medicament for the treatment of a disorder susceptible to treatment with an atypical antipsychotic.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261610664P | 2012-03-14 | 2012-03-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO7091183A2 true CO7091183A2 (en) | 2014-10-21 |
Family
ID=48407766
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO14224666A CO7091183A2 (en) | 2012-03-14 | 2014-10-09 | A metabolite of iloperidone for use in the treatment of psychiatric disorders |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US10874659B2 (en) |
| EP (2) | EP2825167B1 (en) |
| JP (5) | JP2015510893A (en) |
| KR (2) | KR20170008327A (en) |
| CN (2) | CN108938632A (en) |
| AU (2) | AU2013232014B2 (en) |
| BR (1) | BR112014022687A8 (en) |
| CA (1) | CA2865845C (en) |
| CL (1) | CL2014002430A1 (en) |
| CO (1) | CO7091183A2 (en) |
| ES (2) | ES2773711T3 (en) |
| IL (1) | IL234412B (en) |
| IN (1) | IN2014DN08495A (en) |
| MX (1) | MX2014010989A (en) |
| RU (1) | RU2651710C2 (en) |
| WO (1) | WO2013138602A1 (en) |
| ZA (1) | ZA201406369B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016134049A1 (en) | 2015-02-17 | 2016-08-25 | Vanda Pharmaceuticals Inc. | Iloperidone for the treatment of schizophrenia |
| US11214827B2 (en) * | 2018-08-30 | 2022-01-04 | Vanda Pharmaceuticals Inc. | Genetic markers for enhancing efficacy of antipsychotic treatment with iloperidone |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5364866A (en) | 1989-05-19 | 1994-11-15 | Hoechst-Roussel Pharmaceuticals, Inc. | Heteroarylpiperidines, pyrrolidines and piperazines and their use as antipsychotics and analetics |
| US7029694B2 (en) | 2000-04-26 | 2006-04-18 | Watson Laboratories, Inc. | Compositions and methods for transdermal oxybutynin therapy |
| PT2305656E (en) | 2001-08-31 | 2013-01-10 | Novartis Ag | Optical isomers of an iloperidone metabolite |
| AU2002358110A1 (en) | 2001-12-10 | 2003-07-09 | Novartis Ag | Methods of treating psychosis and schizophrenia based on a polymorphism in the ctf gene |
| TW200410955A (en) | 2002-07-29 | 2004-07-01 | Altana Pharma Ag | Novel salt of (S)-PANTOPRAZOLE |
| GB0322994D0 (en) * | 2003-10-01 | 2003-11-05 | Novartis Ag | Organic compounds |
| US8586610B2 (en) | 2004-09-30 | 2013-11-19 | Vanda Pharmaceuticals, Inc. | Methods for the administration of iloperidone |
| US20100063093A1 (en) * | 2007-03-28 | 2010-03-11 | Curt Wolfgang | Methods for the administration of iloperidone |
| MX2008014843A (en) * | 2006-05-22 | 2008-12-05 | Vanda Pharmaceuticals Inc | Treatment for depressive disorders. |
| EP2134873B1 (en) | 2007-03-29 | 2015-05-06 | Vanda Pharmaceuticals Inc. | Method of predicting a predisposition to qt prolongation |
| CA2698534C (en) | 2007-09-10 | 2018-10-09 | Vanda Pharmaceuticals, Inc. | Prediction of qt prolongation based on snp genotype |
| CA2699786C (en) | 2007-09-10 | 2019-08-13 | Vanda Pharmaceuticals, Inc. | Antipsychotic treatment based on snp genotype |
| ES2604102T3 (en) | 2009-04-06 | 2017-03-03 | Vanda Pharmaceuticals Inc. | Treatment method based on polymorphisms of the KCNQ1 gene |
| JP5692872B2 (en) | 2009-04-06 | 2015-04-01 | ヴァンダ ファーマシューティカルズ インコーポレイテッド | Method for predicting predisposition to QT prolongation based on BAI gene sequence or product thereof |
| JP5881597B2 (en) | 2009-04-06 | 2016-03-09 | ヴァンダ ファーマシューティカルズ インコーポレイテッド | How to predict a predisposition to QT prolongation |
| US9074256B2 (en) | 2009-04-06 | 2015-07-07 | Vanda Pharmaceuticals, Inc. | Method of predicting a predisposition to QT prolongation |
| CA2760474C (en) | 2009-05-15 | 2020-08-18 | Vanda Pharmaceuticals Inc. | Antipsychotic treatment based on drd2 or ankk1 snp genotype |
-
2013
- 2013-03-14 AU AU2013232014A patent/AU2013232014B2/en active Active
- 2013-03-14 KR KR1020177001093A patent/KR20170008327A/en active Search and Examination
- 2013-03-14 CA CA2865845A patent/CA2865845C/en active Active
- 2013-03-14 MX MX2014010989A patent/MX2014010989A/en active IP Right Grant
- 2013-03-14 US US14/384,401 patent/US10874659B2/en active Active
- 2013-03-14 ES ES18152636T patent/ES2773711T3/en active Active
- 2013-03-14 IN IN8495DEN2014 patent/IN2014DN08495A/en unknown
- 2013-03-14 EP EP13721817.8A patent/EP2825167B1/en active Active
- 2013-03-14 BR BR112014022687A patent/BR112014022687A8/en not_active Application Discontinuation
- 2013-03-14 RU RU2014141112A patent/RU2651710C2/en active
- 2013-03-14 CN CN201810683727.2A patent/CN108938632A/en active Pending
- 2013-03-14 WO PCT/US2013/031413 patent/WO2013138602A1/en active Application Filing
- 2013-03-14 KR KR1020147026434A patent/KR20140121487A/en active Search and Examination
- 2013-03-14 JP JP2015500615A patent/JP2015510893A/en active Pending
- 2013-03-14 ES ES13721817.8T patent/ES2677474T3/en active Active
- 2013-03-14 CN CN201380013841.XA patent/CN104203240A/en active Pending
- 2013-03-14 EP EP18152636.9A patent/EP3345603B1/en active Active
-
2014
- 2014-08-29 ZA ZA2014/06369A patent/ZA201406369B/en unknown
- 2014-09-01 IL IL234412A patent/IL234412B/en active IP Right Grant
- 2014-09-12 CL CL2014002430A patent/CL2014002430A1/en unknown
- 2014-10-09 CO CO14224666A patent/CO7091183A2/en unknown
-
2016
- 2016-05-30 AU AU2016203591A patent/AU2016203591B2/en active Active
- 2016-11-07 JP JP2016217680A patent/JP2017061506A/en active Pending
-
2018
- 2018-09-10 JP JP2018169090A patent/JP7151029B2/en active Active
-
2020
- 2020-09-28 JP JP2020162569A patent/JP2021001221A/en active Pending
- 2020-09-30 US US17/039,769 patent/US20210015809A1/en not_active Abandoned
-
2022
- 2022-12-01 JP JP2022192922A patent/JP2023022243A/en active Pending
-
2023
- 2023-09-26 US US18/373,205 patent/US20240016791A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ702663A (en) | Nuclear transport modulators and uses thereof | |
| MX2015016983A (en) | Nuclear transport modulators and uses thereof. | |
| DOP2013000192A (en) | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF THE TRK | |
| BR112015029512A8 (en) | pyrazolopyrrolidine derivatives, their uses, and pharmaceutical composition and combination | |
| BR112014032734A2 (en) | pyrrolidine derivatives and their use as complement reaction series modulators | |
| BR112014030678A2 (en) | crystalline forms of an androgen receptor modulator | |
| UA109991C2 (en) | CARBAMATE COMPOUNDS, THEIR PREPARATION AND APPLICATION | |
| BR112014009851A8 (en) | nmda receiver modulators and uses thereof | |
| BR112015018087A8 (en) | compound, pharmaceutical composition and use | |
| AR093247A1 (en) | PROFILACTIC AND / OR THERAPEUTIC AGENT FOR BEHAVIOR AND PSYCHOLOGICAL SYMPTOMS ASSOCIATED WITH NEURODEGENERATIVE DISEASE OR IMPULSIVE SYMPTOMS ASSOCIATED WITH MENTAL ILLNESS CONTAINING BREXPIPRAZOL OR SALTS OF THE SAME | |
| ECSP13013048A (en) | SPIRO- [1,3] -OXACINES AND SPIRO- [1,4] -OXACEPINS AS INHIBITORS | |
| MX2013011908A (en) | Compositions and therapeutic uses of ikk-related kinase epsilon and tankbinding kinase 1 inhibitors. | |
| BR112015029401A8 (en) | pyrazolo-pyrrolidin-4-one derivatives, their uses, and pharmaceutical composition and combination | |
| UY33277A (en) | SPIRO-TETRACICLIC RING COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | |
| BR112016007016A2 (en) | compound or a pharmaceutically acceptable salt thereof, method for symptomatic treatment of cognitive impairment in dementia, and pharmaceutical composition | |
| SG10201805267UA (en) | Piperazine derivatives having multimodal activity against pain | |
| MX2016006604A (en) | Piperidine derivatives having multimodal activity against pain. | |
| AR091706A1 (en) | LAQUINIMOD FORMULATIONS WITHOUT ALKALINIZING AGENTS | |
| DOP2015000071A (en) | COMBINED DRUG THAT INCLUDES GEMIGLIPTINE AND METFORMIN, AND METHOD FOR PREPARATION | |
| BR112015010225A2 (en) | tricyclic compounds and their methods of production and use | |
| UY34896A (en) | TREATMENT OF MULTIPLE SCLEROSIS WITH A COMBINATION OF LAQUINIMOD AND FAMPRIDINE | |
| CL2016001707A1 (en) | Treatment of cognitive disorders with (r) -7-chloro-n- (quinuclidin-3-yl) benzo (b) thiophene-2-carboxamide and pharmaceutically acceptable salts thereof (div. Sol. 1178-11). | |
| PE20151526A1 (en) | TREATMENT OF PROGRESSIVE FORMS OF MULTIPLE SCLEROSIS WITH LAQUINIMOD | |
| AR088204A1 (en) | MEDICINES FOR THE TREATMENT OF ALLERGY RHINITIS THAT INCLUDE A PGD2 ANTAGONIST AND A HISTAMINE ANTAGONIST | |
| UY35253A (en) | PHARMACEUTICAL COMPOUND FOR THE PREVENTION AND TREATMENT OF A COGNITI VOS, NEURODEGENERATIVE OR NEURONAL DISEASE |